ALTEOGEN Inc (196170) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ALTEOGEN Inc (196170) has a cash flow conversion efficiency ratio of 0.041x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩20.99 Billion ≈ $14.22 Million USD) by net assets (₩512.86 Billion ≈ $347.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALTEOGEN Inc balance sheet quality to measure how much of total assets are equity-financed.
ALTEOGEN Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how ALTEOGEN Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 196170 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
ALTEOGEN Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ALTEOGEN Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wise Group plc Class A Ordinary Shares
NASDAQ:WSE
|
N/A |
|
Crown Holdings Inc
NYSE:CCK
|
-0.016x |
|
BUDWEISER BREW.UNSP.ADR/4
F:4BB1
|
N/A |
|
Dongfang Electric Corp Ltd Class A
SHG:600875
|
-0.065x |
|
Littelfuse Inc
NASDAQ:LFUS
|
0.031x |
|
Dayforce Inc.
NYSE:DAY
|
0.012x |
|
Eurofins Scientific SE
F:ESF0
|
0.073x |
|
Erie Indemnity Company
NASDAQ:ERIE
|
0.039x |
Annual Cash Flow Conversion Efficiency for ALTEOGEN Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of ALTEOGEN Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see 196170 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩454.44 Billion ≈ $307.97 Million |
₩124.13 Billion ≈ $84.12 Million |
0.273x | +41.14% |
| 2024-12-31 | ₩274.09 Billion ≈ $185.75 Million |
₩53.04 Billion ≈ $35.95 Million |
0.194x | +468.44% |
| 2023-12-31 | ₩147.84 Billion ≈ $100.19 Million |
₩-7.77 Billion ≈ $-5.26 Million |
-0.053x | +56.29% |
| 2022-12-31 | ₩148.76 Billion ≈ $100.81 Million |
₩-17.87 Billion ≈ $-12.11 Million |
-0.120x | -73.66% |
| 2021-12-31 | ₩136.73 Billion ≈ $92.66 Million |
₩-9.46 Billion ≈ $-6.41 Million |
-0.069x | -700.12% |
| 2020-12-31 | ₩131.16 Billion ≈ $88.89 Million |
₩1.51 Billion ≈ $1.02 Million |
0.012x | -91.17% |
| 2019-12-31 | ₩69.98 Billion ≈ $47.43 Million |
₩9.13 Billion ≈ $6.19 Million |
0.131x | +195.42% |
| 2018-12-31 | ₩66.63 Billion ≈ $45.15 Million |
₩-9.11 Billion ≈ $-6.18 Million |
-0.137x | -25.37% |
| 2017-12-31 | ₩39.85 Billion ≈ $27.00 Million |
₩-4.35 Billion ≈ $-2.95 Million |
-0.109x | -56.21% |
| 2016-12-31 | ₩45.23 Billion ≈ $30.65 Million |
₩-3.16 Billion ≈ $-2.14 Million |
-0.070x | -218.91% |
| 2015-12-31 | ₩38.55 Billion ≈ $26.13 Million |
₩2.26 Billion ≈ $1.53 Million |
0.059x | +73.87% |
| 2014-12-31 | ₩35.82 Billion ≈ $24.28 Million |
₩1.21 Billion ≈ $820.03K |
0.034x | -- |
About ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more